“I think the big pharma companies are going to continue to look outside to find the next wave of innovative therapies,” said Dennis Purcell, senior managing partner of Aisling Capital, a life sciences venture capital firm based in New York
Another factor in the biotech industry’s favor is that regulators have become more supportive of drugs that address high unmet medical needs. In July 2012, the Food and Drug Administration Safety and Innovation Act established the “breakthrough therapy” designation, which gave the agency the authority to speed its review of drugs to treat life-threatening ailments.
“The regulators, notably the F.D.A., have been particularly willing to come up with new strategies to enable the rapid development of drugs for which there is a dramatic effect in a defined patient population,” said Robert Tepper, a partner at Third Rock Ventures, an investor in both Bluebird and Agios. “If you can stratify the patient population you want to treat through genetic analysis, for example, you can move quite quickly through early-stage trials.”
This investment we have is EXTREMELY valuable, as is witnessed by the level of negatives being placed
on this board to keep the retail investor out. Here in London, I assure you they know of INSM, and it's
potential..But the boys in the valley don't want you in this.